Advanced hepatocellular carcinoma
Drug research and approvals for advanced hepatocellular carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 210 studies of advanced hepatocellular carcinoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 13 drug trials for it since 2013.
- Recruiting worldwide: 210
- Trials authorized in Canada: 13
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 210 recruiting on ClinicalTrials.gov ↗- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in…NCT07430202 · Phase 1 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · starts Oct 28, 2026
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaNCT07836530 · Phase 3 · BeOne Medicines · starts Oct 23, 2026
- ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularNCT07813572 · Phase 3 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · starts Oct 20, 2026
- STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular CarcinomaNCT07863258 · Not reported · Universitaire Ziekenhuizen KU Leuven · starts Oct 15, 2026
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerNCT07884877 · Phase 2 · Samsung Medical Center · starts Oct 15, 2026
- Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular CarcinomaNCT07793695 · Phase 2 · Anhui Provincial Hospital · starts Sep 16, 2026
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and…NCT07557251 · Phase 1 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Aug 12, 2026
- Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCCNCT07639138 · Phase 2 · Shunda Du · starts Aug 12, 2026
- A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation…NCT07070076 · Not applicable · Li Qiang · starts Aug 1, 2026
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsNCT07749586 · Phase 1 / Phase 2 · Arvinas Inc. · starts Jul 29, 2026
Trials Authorized in Canada
The 10 newest of 13; search them all in Canada trials| Mar 21, 2025 | A randomized phase 2 study of casdozokitug in combination with toripalimab plus bevacizumab in participants with unresectable and/or locally advanced or…CASDOZOKITUG (SRF388 (CHS-388)) / AVASTIN (BEVACIZUMAB) / TORIPALIMAB | Coherus BioSciences, Inc. | Ongoing |
| Feb 28, 2025 | A phase III, randomised, open-label, sponsor-blinded, multicentre study of rilvegostomig in combination with bevacizumab with or without tremelimumab as…IMJUDO / RILVEGOSTOMIG (AZD2936) / AVASTIN | AstraZeneca Pharmaceuticals LP | Ongoing |
| Dec 30, 2024 | A multicenter, open-label, first-in-human study of tyra-430 in advanced hepatocellular carcinoma and other solid tumors with activating fgf/fgfr pathway…TYRA-430 | TYRA BIOSCIENCES INC. | Ongoing |
| Apr 4, 2023 | A phase 1/2 exploratory study of the tbl1 inhibitor, tegavivint (bc2059), in patients with advanced hepatocellular carcinomaTEGAVIVINT (BC2059) / PEMBROLIZUMAB | ITERION THERAPEUTICS | Pending |
| May 2, 2022 | A phase 1/2, safety confirmation and double-blind, placebo-controlled, randomized study of relatlimab in combination with nivolumab and bevacizumab in…RELATLIMAB (BMS-986016) / OPDIVO / BEVACIZUMAB | Bristol-Myers Squibb | Ongoing |
| Dec 24, 2021 | Phase IIa study of microbial ecosystem therapeutics (met-2 and met-4) to evaluate their effects on fecal microbiome in patients with advanced hepatocellular…MET-2 / MET-4 | NUBIYOTA | Pending |
| Apr 3, 2019 | A randomized, controlled phase 3 study of cabozantinib (xl184) in combination with atezolizumab versus sorafenib in subjects with advanced hepatocellular…CABOZANTINIB/ ATEZOLIZUMAB | Exelixis, Inc. | Ongoing |
| Jun 21, 2017 | Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced hepatocellular carcinoma - a phase II study (pemrad)KEYTRUDA | PRINCESS MARGARET CANCER CENTRE | Ongoing |
| Feb 22, 2017 | A phase Ib study of pdr001 in combination with sorafenib in patients with advanced hepatocellular carcinoma (hcc)PDR001 / FLUDEOXYGLUCOSE 18F / TC99M-MDP | Novartis Pharmaceuticals Corporation | Closed |
| Jul 25, 2016 | An open-label multicenter phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of h3b-6527 in subjects with advanced hepatocellular…H3B-6527 | Eisai | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA